EZZ Life Science Holdings Limited (EZZ.AX)
AUD 2.92
(-0.68%)
AUD 2.92
(-0.68%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 123.85 Thousand AUD | -74.12% |
| 2023 | 478.59 Thousand AUD | 357.67% |
| 2022 | 104.57 Thousand AUD | 32.35% |
| 2021 | 79.01 Thousand AUD | 146.91% |
| 2020 | 32 Thousand AUD | 0.0% |
| 2019 | - AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - AUD | -100.0% |
| 2024 FY | 123.85 Thousand AUD | -74.12% |
| 2024 Q4 | 123.85 Thousand AUD | 0.0% |
| 2024 Q2 | 304.31 Thousand AUD | 0.0% |
| 2023 Q1 | - AUD | -100.0% |
| 2023 FY | 478.59 Thousand AUD | 357.67% |
| 2023 Q4 | 104.57 Thousand AUD | -15.57% |
| 2023 Q3 | 123.85 Thousand AUD | 133.39% |
| 2023 Q2 | 53.06 Thousand AUD | 0.0% |
| 2022 Q1 | - AUD | -100.0% |
| 2022 FY | 104.57 Thousand AUD | 32.35% |
| 2022 Q4 | 104.57 Thousand AUD | 0.0% |
| 2022 Q3 | - AUD | -100.0% |
| 2022 Q2 | 26.73 Thousand AUD | 0.0% |
| 2021 Q1 | - AUD | -100.0% |
| 2021 FY | 79.01 Thousand AUD | 146.91% |
| 2021 Q3 | - AUD | -100.0% |
| 2021 Q4 | 79.01 Thousand AUD | 0.0% |
| 2021 Q2 | 129.75 Thousand AUD | 0.0% |
| 2020 Q4 | 31.72 Thousand AUD | 0.0% |
| 2020 FY | 32 Thousand AUD | 0.0% |
| 2020 Q1 | - AUD | 0.0% |
| 2020 Q3 | - AUD | 0.0% |
| 2019 FY | - AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Zelira Therapeutics Limited | 5.65 Million AUD | 97.809% |
| Biome Australia Limited | 1.3 Million AUD | 90.514% |
| Patrys Limited | - AUD | -Infinity% |
| Orthocell Limited | 689.69 Thousand AUD | 82.042% |
| Imugene Limited | 1.54 Million AUD | 91.993% |
| Noxopharm Limited | - AUD | -Infinity% |
| PYC Therapeutics Limited | 1.11 Million AUD | 88.87% |
| Chimeric Therapeutics Limited | - AUD | -Infinity% |
| Prescient Therapeutics Limited | 330.48 Thousand AUD | 62.523% |
| Proteomics International Laboratories Limited | 316.39 Thousand AUD | 60.854% |
| Cynata Therapeutics Limited | - AUD | -Infinity% |
| CSL Limited | 18.24 Billion AUD | 99.999% |
| Arovella Therapeutics Limited | - AUD | -Infinity% |
| Bio-Gene Technology Limited | - AUD | -Infinity% |
| Clinuvel Pharmaceuticals Limited | 879.78 Thousand AUD | 85.922% |
| Starpharma Holdings Limited | 3.52 Million AUD | 96.489% |
| Nanollose Limited | 42.53 Thousand AUD | -191.22% |
| Memphasys Limited | 4.41 Million AUD | 97.193% |
| Invex Therapeutics Ltd | - AUD | -Infinity% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 1.56 Million AUD | 92.069% |
| Botanix Pharmaceuticals Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 421.96 Thousand AUD | 70.648% |
| Race Oncology Limited | - AUD | -Infinity% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 17.44 Million AUD | 99.29% |
| Dimerix Limited | 149.68 Thousand AUD | 17.254% |
| PharmAust Limited | - AUD | -Infinity% |
| Immutep Limited | 1.22 Million AUD | 89.916% |
| Clarity Pharmaceuticals Ltd | - AUD | -Infinity% |
| Alterity Therapeutics Limited | 159.04 Thousand AUD | 22.125% |
| BTC Health Limited | - AUD | -Infinity% |
| Acrux Limited | 1.48 Million AUD | 91.671% |
| Neuren Pharmaceuticals Limited | - AUD | -Infinity% |
| Biotron Limited | 7130.00 AUD | -1637.111% |
| Tissue Repair Ltd | - AUD | -Infinity% |
| AdAlta Limited | 2.49 Million AUD | 95.035% |
| Radiopharm Theranostics Limited | - AUD | -Infinity% |
| Hexima Limited | - AUD | -Infinity% |
| AnteoTech Limited | 23.59 Thousand AUD | -424.992% |
| Paradigm Biopharmaceuticals Limited | 239.33 Thousand AUD | 48.249% |
| Recce Pharmaceuticals Ltd | 811.19 Thousand AUD | 84.732% |
| Avecho Biotechnology Limited | 175.15 Thousand AUD | 29.286% |
| Actinogen Medical Limited | 319.06 Thousand AUD | 61.182% |
| Immuron Limited | 173.49 Thousand AUD | 28.612% |
| Argenica Therapeutics Limited | - AUD | -Infinity% |